8-K/A: AirSculpt Corrects 2025 Financials After Reporting Errors

AirSculpt Technologies filed an amendment to correct non-GAAP financial measure errors related to its London facility closure.

Summary

• The company filed an 8-K/A to correct errors in Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net Income for the three and twelve months ended December 31, 2025.
• The errors stemmed from an inaccurate one-time non-cash adjustment regarding the closure of the London facility.
• Adjusted EBITDA and Adjusted Net Income were overstated by approximately $2.6 million and $2.7 million respectively, with a net overstatement of $0.1 million.
• Full year 2025 revenue declined 15.8% to $151.8 million, while net loss widened to $11.7 million.
• Case volume for 2025 fell 15.6% to 11,852.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the combination of poor financial performance and the necessity of a restatement, which undermines investor confidence in financial reporting accuracy.

Positives

• Same-store sales turned positive in February 2026.
• The company successfully raised $14.8 million via an at-the-market offering in Q1 2026.
• Debt was reduced by $11.0 million in Q1 2026, bringing gross debt to approximately $45.0 million.
• The company remains in compliance with all debt covenants.

Negatives

• Financial reporting errors required an amendment to the original 8-K filing.
• Revenue declined 15.8% year-over-year for 2025.
• Net loss increased to $11.7 million in 2025 compared to $8.0 million in 2024.
• Adjusted EBITDA dropped to $12.5 million in 2025 from $21.0 million in 2024.
• Case volume experienced a double-digit decline of 15.6% for the full year.

Risks

• Potential inability to raise capital on commercially reasonable terms.
• Risk of dilution to stockholders from future financings.
• Increased competition in the weight loss market, particularly from GLP-1 drugs.
• Failure to stabilize same-store performance.
• Rising operating expenses due to inflation.
• Potential litigation or medical malpractice claims.

Future Outlook

The company projects 2026 revenue of $151 to $157 million and Adjusted EBITDA of $15 to $17 million. Q1 2026 revenue is expected to be $38.5 to $39.5 million.

Management Comments

• Yogi Jashnani noted sequential improvement in same-store sales and emphasized the company's position at the intersection of aesthetics and GLP-1s.
• Management expressed confidence that the current strategy will create meaningful value for shareholders.

Industry Context

StockSavvy.ai notes that AirSculpt is navigating a challenging environment where the rise of GLP-1 weight-loss medications is shifting consumer demand in the aesthetics and body-contouring sector, forcing providers to pivot their marketing and operational strategies.

Comparison to Industry Standards

• The company's double-digit revenue decline contrasts with broader growth trends in the elective cosmetic surgery market.
• The reliance on non-GAAP adjustments to reconcile significant net losses is common in high-growth aesthetic roll-ups but highlights underlying profitability pressures.

Legal Proceedings

• The company mentions potential litigation or medical malpractice claims as a general risk factor.

Stakeholder Impact

• Shareholders face dilution from recent capital raises.
• Creditors are impacted by the company's debt reduction efforts and ongoing covenant compliance.

Next Steps

• Execution of 2026 growth strategy.
• Monitoring of same-store sales performance.
• Continued debt management.

Key Dates

Recommendation

The combination of declining revenue, widening losses, and the need to restate financial results due to calculation errors suggests significant operational and internal control risks that outweigh the potential upside of the current turnaround strategy.

Keywords

AirSculpt, body contouring, aesthetics, financial restatement, AIRS, GLP-1, medical aesthetics